This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
4 Large-Cap Pharma Stocks That Outperformed the S&P This Year
by Zacks Equity Research
We take a look at a few Large Cap stocks, which have surpassed the S&P 500 index in 2017 due to upsides on both regulatory and pipeline fronts.
ImmunoGen (IMGN) Soars Above 200% This Year: Here's Why
by Zacks Equity Research
ImmunoGen's (IMGN) shares shoot up in the year on rapid pipeline progress, positive study data and strategic collaborations.
Pharma Stock Roundup: Roche, MNK Announce Acquisition Agreements, Regulatory Updates from Novartis
by Arpita Dutt
Although it's been a relatively slow week, two acquisition deals were announced with Roche (RHHBY) saying it will acquire Ignyta while Mallinckrodt will buy Sucampo.
Celgene (CELG) in Troubled Waters in '17: What Does 2018 Hold?
by Zacks Equity Research
Celgene's (CELG) stock has been under pressure due to pipeline setbacks. We expect an acquisition in the offing to bolster its portfolio.
Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018?
by Zacks Equity Research
Exelixis (EXEL) had a phenomenal run in 2017 driven by sales of Cabometyx and we expect the momentum to continue in 2018 on the back of the label expansion of the drug.
Roche (RHHBY) Clinches $1.7-Billion Deal to Acquire Ignyta
by Zacks Equity Research
Roche (RHHBY) is set to acquire Ignyta for $27 per share or a total value of $1.7 billion to strengthen its oncology pipeline further.
Celgene (CELG) Down on Discouraging Data on Revlimid
by Zacks Equity Research
Celgene (CELG)'s stock declined as the phase III study, REVELANCE, for the label expansion of key drug Revlimid for untreated follicular lymphoma patients failed.
Cancer Space Update: FDA Approves Label Expansion of 4 Drugs
by Zacks Equity Research
The FDA has approved label expansion of four different drugs from Roche, Exelixis, Pfizer and Bristol-Myers. However, Celgene faced a setback as Revlimid failed in a phase III study.
Roche's Perjeta Gets FDA Nod for Post Surgery Breast Cancer
by Zacks Equity Research
Roche's (RHHBY) Perjeta in combination with Herceptin and chemotherapy (the Perjeta-based regimen), gets FDA nod for adjuvant (after surgery) treatment of HER2-positive early breast cancer at high risk of recurrence
What's Happening in Advanced Renal Cell Carcinoma Space?
by Zacks Equity Research
The advanced renal cell carcinoma space is back in focus as the FDA approved Cabometyx for treatment-naive patients. Investors will keep an eye on other combination therapies being evaluated for the treatment of advanced RCC,
Exelixis' Cabometyx Gets FDA Nod for First-Line Kidney Cancer
by Zacks Equity Research
Exelixis (EXEL) received a significant boost with the approval of label expansion of lead drug Cabometyx for first-line kidney cancer.
AstraZeneca's Tagrisso Label Expansion Filing Accepted by FDA
by Zacks Equity Research
AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include treatment of NSCLC with EGFR mutation in first-line setting has been accepted by the FDA.
Mylan Announces IPR Proceedings for Sanofi's Lantus Patents
by Zacks Equity Research
Mylan (MYL) announced that interpartes review (IPR) proceedings has been initiated by PTAB regarding two Orange Book-listed patents, U.S. Patent Nos. 7,476,652 and 7,713,930 owned by Sanofi.
Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations
by Zacks Equity Research
Several presentations at the annual meeting of the American Society of Hematology grab headlines in the cancer space.
Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook
by Arpita Dutt
This week's pharma sector highlights include ASH data, Teva's restructuring announcement and Lilly's (LLY) 2018 outlook.
Pfizer's Second Biosimilar of Remicade Receives FDA Approval
by Zacks Equity Research
The FDA approves Ixifi, Pfizer's (PFE) second biosimilar version of Johnson & Johnson's rheumatoid arthritis drug, Remicade. Ixifi receives the nod for all approved indications of Remicade.
Roche/AbbVie Report Positive Phase III Results on Venclexta
by Zacks Equity Research
Roche (RHHBY) announced positive results from a pivotal phase III study, MURANO, evaluating Venclexta plus Rituxan compared to bendamustine plus Rituxan (BR) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).
Novartis Announces Positive Data on Sickle Cell Disease Drug
by Zacks Equity Research
Novartis (NVS) announced positive data from a phase II study, SUSTAIN, on pipeline candidate crizanlizumab which deferred the time to first sickle cell pain crisis (SCPC) in patients compared to placebo in key subgroups of adult patients with sickle cell.
Roche Reports Positive Data from Tecentriq Combination Study
by Zacks Equity Research
Roche reported positive data from a combination study of Tecentriq and Avastin in metastatic renal cell carcinoma patients.
Foreign Stock Roundup: Bank of Montreal Q4 Earnings Decline, Rio Tinto Lowers '17 Capital Spending Target
by Swarup Gupta
Investors in Europe remained focused on Brexit negotiations and the Senate's decision to approve a new tax Bill last week.
Puma (PBYI) Stock Up More than 200% This Year: Here's Why
by Zacks Equity Research
Puma's (PBYI) shares skyrocket in the year so far on the approval of its cancer drug Nerlynx in the United States coupled with strategic collaborations.
Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz
by Arpita Dutt
FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.
Roche Reports Tecentriq/Avastin Lung Cancer Study Data
by Zacks Equity Research
Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer.
Clovis' sNDA for Rubraca Gets Priority Review in the U.S.
by Zacks Equity Research
The FDA grants priority review to Clovis' (CLVS) supplemental new drug application for its marketed drug, Rubraca's label expansion as a maintenance treatment for ovarian cancer.
Roche's Avastin Gets Full FDA Approval for Brain Cancer
by Zacks Equity Research
Roche (RHHBY) announced that the FDA converted accelerated approval for Avastin to full approval for the patients previously treated for aggressive form of brain cancer.